• vcard
D 312.873.3633
F 312.602.3922
  • Education
    • J.D., cum laude, John Marshall Law School, 2011, Order of John Marshall; Fred F. Herzog Scholarship; Dean's Scholarship
    • Ph.D., University of Wisconsin, 2002, Genetics
    • B.A., University of California, Berkeley, 1995, with High Honors and with Distinction in General Scholarship
  • Bar Jurisdictions
    • Illinois, 2011
    • Admitted to practice before the United States Patent and Trademark Office
A scientist, businessman and lawyer, Ron Galant brings all facets of his experience to bear when counseling clients on a variety of intellectual property issues.

Whether it's patent prosecution strategy, intellectual property licensing, or a patent invalidity or non-infringement opinion, clients can depend on Ron's unique perspective to achieve their goals.

Ron has significant experience in the following areas:
  • Patent prosecution and preparation in many technology areas, including pharmaceuticals, biologics, and molecular and medical diagnostics
  • Intellectual property licensing and other technology transfer agreements
  • Patent invalidity and non-infringement opinions

Ron developed his patent prosecution expertise while working as a patent agent at Polsinelli. He also gained experience in the pharmaceutical industry as manager of medical writing at a contract research organization where he helped design clinical trials and prepare clinical study reports.

Previously, Ron worked in business development at a biotechnology company that had developed an industrial-scale gene-screening platform. His education includes multi-disciplinary graduate research that led to completion of a doctorate and publications in leading scientific journal.
  • Wrote and prosecuted patent applications leading to issued patents in multiple jurisdictions in a variety of technology areas.
  • Successfully reversed an examiner's patent claim rejection on appeal with U.S. Patent and Trademark Office Board of patent appeals and interferences.
  • Drafted an intellectual property license agreement for a client to license a protein-based drug technology.
  • Wrote a patent invalidity opinion for a major generic drug company in preparation for a first-to-file Abbreviated New Drug Application.
  • Performed intellectual property due diligence in merger and acquisition of a target technology company.
  • Reviewed and revised technology licensing contracts with Fortune 500 companies for client's web-based virtual event presentation platform.
Publications & Presentations
A Multi-Center, Open Label Study to Evaluate Satisfaction and Menopausal Quality of Life in Women Using Transdermal Estradiol/Norethindrone Acetate Therapy for the Management of Menopausal Signs and Symptoms
Gynecologic and Obstetric Investigation
Co-author
2005
Publications & Presentations
Hox Repression of a Target Gene: Extradenticle-Independent, Additive Action Through Hox Repression of a Target Gene: Extradenticle-Independent, Additive Action Through Multiple Monomer Binding Sites
Development
First Author
2002
Publications & Presentations
Evolution of a Novel Transcriptional Repression Domain in the Ultrabithorax Hox Protein in Insects
Nature
First Author
2002
Related News